GCIA
CLVS

Gabelli & Co Investment Advisers’s Clovis Oncology, Inc. CLVS Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-40,100
Closed -$2.12M – 172
2018
Q1 		$2.12M Buy
40,100
+5,400
+16% +$315K 0.27% 55
2017
Q4 		$2.36M Buy
34,700
+5,300
+18% +$371K 0.31% 53
2017
Q3 		$2.42M Buy
29,400
+8,700
+42% +$690K 0.28% 55
2017
Q2 		$1.94M Buy
20,700
+14,000
+209% +$857K 0.21% 58
2017
Q1 		$427K Buy
+6,700
New +$407K 0.05% 109

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Gabelli & Co Investment Advisers's CLVS Position: Q2 2018 in Review

Gabelli & Co Investment Advisers sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 40,100 shares — an estimated $2.12M sold.

Gabelli & Co Investment Advisers first reported a position in CLVS in Q1 2017 and held it in 5 quarters. The position peaked at $2.42M in Q3 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • Gabelli & Co Investment Advisers reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 40,100 Clovis Oncology, Inc. shares in Q2 2018, an estimated $2.12M.
  • Gabelli & Co Investment Advisers first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 5 quarters.
  • Gabelli & Co Investment Advisers's Clovis Oncology, Inc. position peaked at $2.42M in Q3 2017.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on Gabelli & Co Investment Advisers's 13F filing for Q2 2018, filed 10 Aug 2018.